drugset / Trial / NCT01206608

Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty

NCT01206608

Phase 2 Completed 40 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to demonstrate the superiority of SKY0402 over conventional, commercially-available bupivacaine HCl with respect to the duration of the analgesic effect achieved by a single local administration of the study drug.

Timeline

Start
2008-03
Primary completion
2008-08
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 75 mg Other
Comparator SKY0402 Unknown Other

Indications

No indication recorded.